S&P Futures
4,141.75 -5.00 (-0.12%) Dow Futures
32,736.00 -21.00 (-0.06%) Nasdaq Futures
13,224.00 -4.75 (-0.04%) Russell 2000 Futures
1,920.20 -1.60 (-0.08%) Crude Oil
89.56 +0.55 (+0.62%) Gold
1,788.80 -2.40 (-0.13%)
Appili Therapeutics Inc. (APLIF)
Chart Events
Performance Outlook
| Previous Close | 0.0484 |
| Open | 0.0484 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0484 - 0.0484 |
| 52 Week Range | 0.0450 - 0.9020 |
| Volume | |
| Avg. Volume | 12,483 |
| Market Cap | 6.595M |
| Beta (5Y Monthly) | 0.89 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3190 |
| Earnings Date | Aug 11, 2022 - Aug 15, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for APLIF
Related Research
- APPILI THERAPEUTICS INCAnalyst Report: BioNTech SEBioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.RatingFair ValueEconomic Moat5 days agoMorningstar
- Business Wire
Appili Therapeutics to Present at WorldLeish7 Conference in Cartagena, Columbia
HALIFAX, Nova Scotia, August 02, 2022--Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that Armand Balboni, M.D, Ph.D, Chief Executive Officer, and Yoav Golan, M.D, Chief Medical Officer of Appili, will participate at the seventh iteration of WorldLeish, from August 1 to 6 2022, and present an update on Appili program ATI-1801.
- Zacks Small Cap Research
APLIF: New Late Stage Program to Treat Cutaneous Leishmaniasis…
Bautz: By David Bautz, PhD OTC:APLIF | TSX:APLI.TO READ THE FULL APLIF RESEARCH REPORT Business Update New Late-Stage Program in Cutaneous Leishmaniasis On April 13, 2022, Appili Therapeutics Inc. (OTC:APLIF) (TSX:APLI.TO) announced the addition of ATI-1801, a late stage clinical program to treat cutaneous leishmaniasis. The product, a topical formulation of paromomycin, was licensed from the
- Business Wire
Appili Therapeutics Reports Fiscal Year 2022 Financial and Operational Results
HALIFAX, Nova Scotia, June 29, 2022--Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the fiscal year ended March 31, 2022, and provided an update on the Company’s strategy for fiscal 2023. All figures are stated in Canadian dollars unless otherwise stated.
